Loading…
MediciNova, Inc. is projected to rise to $1.37 by 2027, a +3% move from its current price of $1.33. MNOV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.31 | $1.33 | $1.36 | +0.03% |
| Aug 6 | $1.30 | $1.33 | $1.37 | +0.06% |
| Aug 7 | $1.29 | $1.33 | $1.37 | +0.08% |
| Aug 8 | $1.28 | $1.33 | $1.38 | +0.11% |
| Aug 9 | $1.28 | $1.33 | $1.39 | +0.14% |
| Aug 10 | $1.27 | $1.33 | $1.39 | +0.17% |
| Aug 11 | $1.27 | $1.33 | $1.40 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.27 | $1.33 | $1.40 | +0.20% |
| Week 2 | $1.25 | $1.34 | $1.43 | +0.39% |
| Week 3 | $1.23 | $1.34 | $1.46 | +0.59% |
| Week 4 | $1.22 | $1.34 | $1.48 | +0.78% |
| Week 5 | $1.20 | $1.34 | $1.50 | +0.98% |
| Week 6 | $1.19 | $1.35 | $1.52 | +1.18% |
| Week 7 | $1.18 | $1.35 | $1.54 | +1.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MediciNova, Inc. is a biopharmaceutical company focused on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
MediciNova (MNOV) is currently trading at $1.31. The stock has a market cap of $65.46M and is ranked 5512. The long-run price outlook shows meaningful upside according to the year-by-year forecast, with 2030 avg price $2.00 and 2050 avg price $7.76, and 2050 max $12.70; ROIs of 52.6% in 2030 and 492.6% in 2050.
For 2026, the forecast shows an avg price of $1.31 with NEUTRAL sentiment.
A major floor 9.5% below — a decisive break under it would weaken the trend.
The nearest floor, 3.0% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 13.0% above — clearing it would confirm fresh momentum.
Key MNOV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MNOV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.32 | Buy | $1.33 | Buy |
| MA 10 | $1.32 | Buy | $1.33 | Sell |
| MA 20 | $1.36 | Sell | $1.34 | Sell |
| MA 50 | $1.34 | Sell | $1.35 | Sell |
| MA 100 | $1.38 | Sell | $1.38 | Sell |
| MA 200 | $1.42 | Sell | $1.40 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.49 | Neutral |
| Stoch RSI (14) | 41.52 | Neutral |
| CCI (20) | -53.96 | Neutral |
| Williams %R (14) | -69.23 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -5.00 | Sell |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 30.77 | Neutral |
| TRIX (15) | -0.04 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 48.85 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 1.32 | Buy |
| ADX (14) | 11.13 | Neutral |
| ATR (14) | 0.02 | Info |
The near-term technical picture is BEARISH, with RSI14 at 40. The stock is trading below the 50-day simple moving average of $1.35 and below the 200-day SMA of $1.42, signaling near-term weakness. Key levels are a support at $1.23 and a resistance at $1.44, and the 30-day range runs from $1.16 to $1.48.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.23 | $1.33 | $1.69 | 0% | Neutral | |
| $1.13 | $1.37 | $1.75 | +3% | Neutral | |
| $1.18 | $1.46 | $1.91 | +10% | Neutral | |
| $1.37 | $1.73 | $2.31 | +30% | Bullish | |
| $1.54 | $1.96 | $2.68 | +48% | Bullish | |
| $1.68 | $2.18 | $3.01 | +64% | Bullish | |
| $1.71 | $2.24 | $3.15 | +69% | Bullish | |
| $1.69 | $2.24 | $3.18 | +68% | Bullish | |
| $1.87 | $2.50 | $3.60 | +88% | Bullish | |
| $1.98 | $2.67 | $3.88 | +101% | Bullish | |
| $2.63 | $3.71 | $5.65 | +179% | Bullish | |
| $5.01 | $7.57 | $12.37 | +469% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.23 | $1.33 | $1.60 | +0.00% |
| September 2026 | $1.14 | $1.34 | $1.60 | +0.67% |
| October 2026 | $1.16 | $1.36 | $1.65 | +1.88% |
| November 2026 | $1.18 | $1.40 | $1.70 | +2.62% |
| December 2026 | $1.16 | $1.38 | $1.69 | -1.38% |
Click any year to see its month-by-month MNOV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MNOV is projected to trade between $1.23 and $1.69, averaging $1.33 — a potential gain of 0% from today's $1.33. A consolidation phase looks the most probable path here.
MediciNova, Inc.'s 2027 outlook centres on $1.37, within a $1.13 to $1.75 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2028, MNOV could reach as high as $1.91, with a base case around $1.46 and support toward $1.18 — roughly +10% from $1.33. A consolidation phase looks the most probable path here.
Expect MNOV to range from $1.37 to $2.31 through 2029. The $1.73 average target implies a +30% move from current prices. That is up +18% on the projected 2028 average. Momentum favours further upside here.
The MNOV price prediction for 2030 points to an average of $1.96 (low $1.54, high $2.68) — a potential gain of +48% on today's $1.33. Buyers look set to stay in control over this stretch.
In 2031, MNOV is projected to trade between $1.68 and $3.01, averaging $2.18 — a potential gain of +64% from today's $1.33. That is up +11% on the projected 2030 average. Momentum favours further upside here.
MediciNova, Inc.'s 2032 outlook centres on $2.24, within a $1.71 to $3.15 range. That is up +3% on the projected 2031 average. That marks a +69% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, MNOV could reach as high as $3.18, with a base case around $2.24 and support toward $1.69 — roughly +68% from $1.33. Momentum favours further upside here.
Expect MNOV to range from $1.87 to $3.60 through 2034. The $2.50 average target implies a +88% move from current prices. That is up +12% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The MNOV price prediction for 2035 points to an average of $2.67 (low $1.98, high $3.88) — a potential gain of +101% on today's $1.33. Momentum favours further upside here.
In 2040, MNOV is projected to trade between $2.63 and $5.65, averaging $3.71 — a potential gain of +179% from today's $1.33. That is up +39% on the projected 2035 average. Buyers look set to stay in control over this stretch.
MediciNova, Inc.'s 2050 outlook centres on $7.57, within a $5.01 to $12.37 range. That is up +104% on the projected 2040 average. That marks a +469% change versus current levels. Momentum favours further upside here.
Investing $1,000 in MNOV today (≈ 751.879699 MNOV) could be worth
$5,691.28
+$4,691.28 (+469%) by 2050 · US Dollar
Based on the average projected MNOV price of $7.57 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MNOVwould be worth at today's price.
$1,000 invested in MNOV on Jul 31, 2025 (≈ 751.879675 MNOV) would be worth
$1,000
-$0 (-0.0%) today · 1.00× · US Dollar
Based on a MNOV entry price of $1.33 vs. today's $1.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.32 | $1,007.58 | +0.8% |
| 1 month ago | $1.42 | $936.62 | -6.3% |
| 3 months ago | $1.4 | $950 | -5.0% |
| 6 months ago | $1.66 | $801.2 | -19.9% |
| 1 year ago | $1.33 | $1,000 | -0.0% |
| All time (5.0y) ago | $3.65 | $364.38 | -63.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MNOV forecast.
Our base-case forecast reaches $2.70 around 2040.
Implied market cap at $2.70: $132.9M
The multi-year forecast shows a bullish trajectory beginning in 2029, with 2029 avg $1.74 and max $2.33 and ROI 32.7%. By 2030 the avg is $2.00 with a max of $2.72 and ROI of 52.6%. The 2040 forecast envisions an avg of $3.84, a max of $5.86 and ROI of 193.1%.
By 2050 the min is $5.14, the avg is $7.76 and the max is $12.70, with an ROI of 492.6%. Sentiment shifts to BULLISH from 2029 onward and remains BULLISH through 2050. These are estimates, not guarantees, and are subject to market conditions and clinical outcomes; the asset shows notable upside potential but also inherent volatility (annualized volatility 40%).
Tap a question to reveal the answer.
Min $1.56, avg $2.00, max $2.72; ROI 52.6%; sentiment BULLISH.
The forecast shows rising averages and bullish sentiment from 2029 onward, with 2030 avg $2.00, 2030 max $2.72, 2040 avg $3.84 and 2050 avg $7.76 with a max of $12.70 and ROI up to 492.6%. Near term, 2026 sentiment is NEUTRAL and the short-term picture is BEARISH, so results depend on timing and conditions.
Yes. The 2040 max is $5.86 and the 2050 max is $12.70, so reaching $5 could occur by 2040 according to the forecast.
Current price is $1.31 and market cap is $65.46M.
Bearish sentiment with RSI 14 at 40. The price is below SMA50 at $1.35 and SMA200 at $1.42, with support at $1.23 and resistance at $1.44. The 30-day range is $1.16 to $1.48.
MediciNova, Inc. Community Discussion
0Share your MediciNova, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.